Cerebral amyloid load determination in a clinical setting: interpretation of amyloid biomarker discordances aided by tau and neurodegeneration measurements-Reference-Cited by-同舟云学术

Cerebral amyloid load determination in a clinical setting: interpretation of amyloid biomarker discordances aided by tau and neurodegeneration measurements

Published:2021-11-05 Issue: Volume: Page:
ISSN:1590-1874
Container-title:Neurological Sciences
language:en
Short-container-title:Neurol Sci

Author:

Nerattini Matilde^ORCID,Rubino Federica,Arnone Annachiara,Polito Cristina,Mazzeo Salvatore,Lombardi Gemma,Puccini Giulia,Nacmias Benedetta,De Cristofaro Maria Teresa,Sorbi Sandro,Pupi Alberto,Sciagrà Roberto,Bessi Valentina,Berti Valentina

Publisher

Springer Science and Business Media LLC

Subject

Psychiatry and Mental health,Clinical Neurology,Dermatology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s10072-021-05704-2.pdf

Reference41 articles.

1. Jack CR, Bennett DA, Blennow K et al (2018) NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement 14(4):535–562

2. De Wilde A, Reimand J, Teunissen CE et al (2019) Discordant amyloid-β PET and CSF biomarkers and its clinical consequences. Alzheimers Res Ther 11(1):78 (Published 2019 Sep 12)

3. Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer’s disease. Lancet 368(9533):387–403

4. Palmqvist S, Mattsson N, Hansson O (2016) Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography. Brain 139(Pt 4):1226–1236

5. Clark CM, Pontecorvo MJ, Beach TG et al (2012) Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. Lancet Neurol. 2012 Aug;11(8):658]. Lancet Neurol 11(8):669–678